How could the proposed Medicare payment cut for 340B drugs affect Eli Lilly and Company?
Eli Lilly and Company may face changes in revenue due to proposed Medicare drug payment cuts The HHS brief argues that the 340B program incentivizes hospitals to overuse high-cost drugs because they keep the difference between the discounted purchase price and the standard Medicare payment rate. The Centers for Medicare and Medicaid Services (CMS) is currently proposing a major cut to these payments, changing the reimbursement rate from the average sales price plus 6% to the average sales price minus 33.4%. If finalized, this reduction in Medicare payments for 340B-acquired drugs could alter the financial model and pricing strategy for pharmaceutical companies like Eli Lilly and Company, which supply drugs to these programs.
- Effect
- Mild negative
- How direct
- Brind's reasoning
- When
- Within months
- The story
- No new developments lately
How it reaches Eli Lilly and Company
-
Economists at the Department of Health and Human Services produced an internal agency analysis arguing that the federal drug discount program, the 340B Program, may incentivize hospitals to overuse expensive drugs and expand through consolidation. The analysis, which was authored by Casey B. Mulligan, supports a Medicare payment cut that the administration has proposed. Hospital groups have strongly opposed this proposed cut.
The full event1independent outlet -
The 340B program requires drugmakers to sell outpatient drugs at reduced prices, estimated at 20% to 50% of a drug's cost, to qualifying hospitals. The proposed payment cut changes the reimbursement structure, which directly affects the revenue and pricing dynamics for pharmaceutical companies that participate in the 340B program, such as Eli Lilly and Company.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
American pharmaceutical company
Everything about Eli Lilly and Company
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The 340B program requires drugmakers to sell outpatient drugs at reduced prices, estimated at 20% to 50% of a drug's cost, to qualifying hospitals.medicaldaily.com
- Hospitals buy drugs at the discounted price but are paid by Medicare at a standard rate, currently the average sales price plus 6%.medicaldaily.com
- Under the CMS proposal, Medicare would pay for 340B-acquired drugs at the average sales price minus 33.4%.medicaldaily.com
- CMS estimated the change would reduce Original Medicare drug payments by about $4.55 billion in the first year.medicaldaily.com
Why it matters
The 340B program is designed to help safety-net hospitals serve low-income and uninsured patients by providing drug discounts. However, the HHS brief argues that the current payment structure creates incentives for hospitals to overuse high-cost drugs, which ultimately contributes to rising healthcare costs for consumers.
For pharmaceutical companies, the 340B program represents a critical revenue stream tied to public health initiatives. A significant shift in Medicare's reimbursement policy, as proposed by CMS, could fundamentally change the financial viability of participation in this program, forcing drugmakers to adjust their pricing and distribution strategies.
What we don't know yet
- Will the CMS proposal for the 340B payment cut be finalized into a rule?
- How will participating drugmakers adjust their pricing models if the reimbursement rate is lowered?
What would change this answer
— Other considerations
Beyond this explainer
Questions worth asking
Ideas the web ties closely to this story that the explainer doesn't mention. These are prompts for your own research: Brind hasn't answered them.
-
About NPPES
Since the 340B program relies on specific qualifying hospitals, how might changes to the CMS provider tracking system affect which hospitals qualify for the discount?
Explore NPPES -
About CDC Prevention
Given that the 340B program is designed to help safety-net hospitals serve low-income patients, how might a reduction in drug payments impact the ability of these hospitals to maintain public health services?
Explore CDC Prevention -
About ESRD
Since safety-net hospitals serve vulnerable populations, how might the proposed payment cut specifically affect the treatment costs for patients with End-Stage Renal Disease?
Explore ESRD
Explore connected ideas
Each opens a map of what the web connects to it, with Brind's news on it.
The ideas come from how millions of web pages place them near each other. The questions are Brind's AI reasoning, written only from this explainer and Brind's own reporting.
Who else could feel it
Other possible ripples from the same event.
Reporting
- medicaldaily.comSaturday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.